<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946631</url>
  </required_header>
  <id_info>
    <org_study_id>GDM 2019 iris 01-18-0028</org_study_id>
    <nct_id>NCT03946631</nct_id>
  </id_info>
  <brief_title>GDM Post Partum Screening</brief_title>
  <official_title>Immediate Postpartum Screening for Diabetes Mellitus in Women With Gestational Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mednax Center for Research, Education, Quality and Safety</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banner University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mednax Center for Research, Education, Quality and Safety</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immediate postpartum screening for diabetes mellitus in women with gestational diabetes

      The objective of this study is to determine if screening for type 2 diabetes can be done 24
      hours after delivery, versus 6-12 weeks postpartum, in recently delivered women having been
      diagnosed with gestational diabetes requiring medication therapy in the antecedent pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1 Overview The purpose of the project is to determine if screening for diabetes mellitus, in
      women with gestational diabetes, can be done 24 hours postpartum versus 6-12 weeks
      postpartum.

      Primary Objective: To compare the results from screening for type 2 diabetes 24 hours
      postpartum versus 6-12 weeks postpartum.

      Design and Project Type Prospective cohort study. Women diagnosed with gestational diabetes
      and receiving anti-hyperglycemic medication therapy will have testing for type 2 DM done 24
      hours after delivery. They will also have routine screening for type 2 DM done at 6-12 weeks
      postpartum.

      Description of Intervention The intervention is early screening for type 2 DM which involves
      oral intake of a 75-- gram (g) glucose drink and subsequent measurement of fasting, 1- hour,
      and 2- hour postprandial point of care fingerstick s for blood glucose measurement.

      Instruments Fingerstick testing will be done with StatStrip Glucose Hospital Meter (Nova
      Biomedical). This device is used routinely throughout the hospital and has been validated for
      use in all patients, including the critically ill. Using point of care testing will allow for
      accurate results with less pain for the patient, as compared to (fingerstick versus
      venipuncture).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.</measure>
    <time_frame>24-48 hours postpartum verses 6-12 weeks postpartum.</time_frame>
    <description>We will compare the sensitivity of a 2-hour oral glucose tolerance test (2HR OGTT) for the detection of overt diabetes when performed within 48 hours of delivery (&quot;early&quot;) among postpartum women previously diagnosed with gestational diabetes requiring treatment. The &quot;early&quot; 2HR OGTT result will be compared to the current standard of care of a 2HR OGTT performed at 6-12 weeks postpartum.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetes</condition>
  <condition>Gestational Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Blood Glucose Test - 2hour GTT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2 hour glucose tolerance test using 75g glucose drink</intervention_name>
    <description>intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.</description>
    <arm_group_label>Blood Glucose Test - 2hour GTT</arm_group_label>
    <other_name>fingerstick testing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant, or recently postpartum, women with the diagnosis of GDM requiring medication
             therapy after 20 weeks,

          -  &gt;18 years-old (yo)yo,

          -  English speaking.

        Exclusion Criteria:

          -  have pre-existing type 2 DM,

          -  did not require anti-hyperglycemic medication therapy (GDMA1),

          -  early onset GDM (&lt;20 weeks).

          -  do not speak English .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant females with current diagnosis of type 2 DM or gestational diabetes</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Wilkes</last_name>
    <role>Study Director</role>
    <affiliation>Banner University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kisti Fuller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Perinatal Associates, Mednax</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Bodea Braescu, MSN, MPH, RN</last_name>
    <phone>602-614-0488</phone>
    <email>ana_braescu@mednax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Leovic, MD</last_name>
    <phone>480-969-5999</phone>
    <email>michael_leovic@mednax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner - University Medical Center Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Braescu, RN</last_name>
      <phone>602-257-8118</phone>
      <email>ana_braescu@mednax.com</email>
    </contact>
    <contact_backup>
      <last_name>RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kisti Fuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>GÃ¶bl CS, Bozkurt L, Prikoszovich T, Winzer C, Pacini G, Kautzky-Willer A. Early possible risk factors for overt diabetes after gestational diabetes mellitus. Obstet Gynecol. 2011 Jul;118(1):71-8. doi: 10.1097/AOG.0b013e318220e18f.</citation>
    <PMID>21691165</PMID>
  </reference>
  <reference>
    <citation>Su X, Zhang Z, Qu X, Tian Y, Zhang G. Hemoglobin A1c for diagnosis of postpartum abnormal glucose tolerance among women with gestational diabetes mellitus: diagnostic meta-analysis. PLoS One. 2014 Jul 11;9(7):e102144. doi: 10.1371/journal.pone.0102144. eCollection 2014.</citation>
    <PMID>25014072</PMID>
  </reference>
  <reference>
    <citation>Mendez-Figueroa H, Daley J, Breault P, Lopes VV, Paine V, Goldman D, Francis MJ, Delgado B, Coustan DR. Impact of an intensive follow-up program on the postpartum glucose tolerance testing rate. Arch Gynecol Obstet. 2014 Jun;289(6):1177-83. doi: 10.1007/s00404-014-3157-0. Epub 2014 Jan 31.</citation>
    <PMID>24481876</PMID>
  </reference>
  <reference>
    <citation>Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing. Diabetes. 1995 May;44(5):586-91.</citation>
    <PMID>7729620</PMID>
  </reference>
  <reference>
    <citation>5. Biljok VR, Bozicevic S, Lovrencic MV, Car N. Performance of the StatStrip Glucose Meter in Inpatient Management of Diabetes Mellitus. Diabetologia Croatica 2010; 39-3:105-109.</citation>
  </reference>
  <reference>
    <citation>Werner EF, Has P, Tarabulsi G, Lee J, Satin A. Early Postpartum Glucose Testing in Women with Gestational Diabetes Mellitus. Am J Perinatol. 2016 Aug;33(10):966-71. doi: 10.1055/s-0036-1583193. Epub 2016 Apr 27. Erratum in: Am J Perinatol. 2016 Dec;33(14 ):1433-1434.</citation>
    <PMID>27120481</PMID>
  </reference>
  <reference>
    <citation>Dinglas C, Muscat J, Heo H, Islam S, Vintzileos A. Immediate Postpartum Glucose Tolerance Testing in Women with Gestational Diabetes: A Pilot Study. Am J Perinatol. 2017 Oct;34(12):1264-1270. doi: 10.1055/s-0037-1606620. Epub 2017 Sep 14.</citation>
    <PMID>28910846</PMID>
  </reference>
  <reference>
    <citation>VuÄiÄ LovrenÄiÄ M, RadiÅ¡iÄ Biljak V, BoÅ¾iÄeviÄ S, Pape-MedvidoviÄ E, LjubiÄ S. Validation of Point-of-Care Glucose Testing for Diagnosis of Type 2 Diabetes. Int J Endocrinol. 2013;2013:206309. doi: 10.1155/2013/206309. Epub 2013 Dec 8.</citation>
    <PMID>24382960</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

